The murky path to drug discovery in ALS becomes clearer

The Lancet Neurology

Volumn 12, Issue 11, 2013, Pages 1037-1038

  Gordon, Paul H ^a  

^a Northern Navajo Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXPRAMIPEXOLE; DOPAMINE; LEVODOPA; RILUZOLE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL ACTIVITY; DRUG DEVELOPMENT; DRUG SAFETY; DRUG SCREENING; HEALTH CARE COST; HUMAN; LETTER; METAMORPHOSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANTS; BENZOTHIAZOLES; FEMALE; HUMANS; MALE;

EID: 84885383793     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70224-2     Document Type: Letter

References (13)

1. Cudkowicz M, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013, for the EMPOWER investigators, published online Sept 23. http://dx.doi.org/10.1016/S1474-4422(13)70221-7.
2. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A The current and projected economic burden of Parkinson's disease in the United States. Mov Disord 2013, 28:311-318.
3. Cotzias GC, Van Woert MH, Schiffer LM Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967, 276:374-379.
4. Sacks O The origin of "Awakenings". Br Med J (Clin Res Ed) 1983, 287:1968-1969.
5. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996, 347:1425-1431. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
6. Bensimon G, Lacomblez L, Meininger V A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994, 330:585-591. ALS/Riluzole Study Group.
7. Scott S, Kranz JE, Cole J, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 2008, 9:4-15.
8. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011, 17:1652-1656.
9. Palesch YY, Tilley BC An efficient multi-stage, single-arm phase II futility design for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004, 5(suppl 1):55-56.
10. Cheung YK, Gordon PH, Levin B Selecting promising ALS therapies in clinical trials. Neurology 2006, 67:1748-1751.
11. Cudkowicz ME, Katz J, Moore DH, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010, 11:259-265.
12. Gordon PH, Cheung YK, Levin B, et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler 2008, 9:212-222.
13. Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009, 66:235-244.